Table 1 Trial characteristics

GHT2000 [21]

Inactive 18–74-year-olds with hypertension, suspected hypertension, pre-hypertension or high-normal blood pressure

Interventions: (i) GP gym-based referral plus web tool, (ii) sport referral (iii) sport referral plus web tool

Comparator: GP gym-based referral

Individually randomised four-arm group trial

Two-arm trial, individually randomised

PSM COPD [22]

COPD patients aged 18 years or older with mild dyspnoea

Intervention: a telephone-based self-management intervention

Comparator: usual care

Individually randomised two-arm group trial

Two-arm trial, clustered by general practice

HI-Light [23]

Patients aged 5 years and over with vitiligo

Interventions: (i) Handheld narrowband UVB (NB-UVB) and (ii) a combination of potent topical corticosteroid and NB-UVB, compared with potent topical corticosteroid

Individually randomised three-arm, placebo-controlled

Two-arm trial, individually randomised

seAFOod [24]

Patients aged 55–73 years identified during screening colonoscopy as being at ‘high risk’ for subsequent surveillance colonoscopy

Interventions: (i) 2 g eicosapentaenoic acid per day and (ii) 300 mg aspirin per day

Comparator: placebo

Individually randomised 2 by 2 factorial trial

Two-arm trial, cluster randomised ( Endoscopy Unit taking part in the UK NHS Bowel Cancer Screening Programme)

STOP ACEi [20]

Patients with advanced progressive CKD receiving angiotensin-converting enzyme inhibitor or angiotensin receptor blockers (or both)

Intervention: Discontinue Angiotensin Converting enzyme inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) or combination of both

Comparator: Continue ACEi, ARB or combination of both

Individually randomised two-arm group trial

Two-arm trial, individually randomised